The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Tags · Evidence

randomised trial

Randomised controlled trial evidence.

174 topics 62 solved Group: Evidence

Related in this group: STEP programme · SURMOUNT programme · SURPASS programme · SELECT trial · FLOW trial · SOUL trial · TRIUMPH programme · PIONEER programme · SUSTAIN programme · LEADER trial · meta-analysis · observational data

174 topics · page 2 of 6

TopicParticipantsRepliesViewsActivity
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit?
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first…
AWBWCEPLEK+5 9 30k 8d
[2026 update] Journal club: FLOW and the renal composite, component by component
Journal club: FLOW and the renal composite, component by component Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what…
NBTAC 2 21k 9d
Tirzepatide storage and stability: what is published versus what is assumed
On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Asking about tirzepatide storage and stability directly,…
APPOELIGR+17 21 17k 12d
Interim analyses and stopping rules
Interim analyses and stopping rules Writing it up because I had to work it out twice and would rather nobody else did. Asking about interim analyses and stopping rules on behalf of the question I keep seeing…
TKHJRIGEL+25 29 35k 16d
Why fasting instructions for oral semaglutide are not optional advice
Why fasting instructions for oral semaglutide are not optional advice I have a specific reason for asking rather than idle curiosity, and the context is below. Fasting instructions for oral semaglutide, from…
HFGHNNJAS+70 74 1.1k 23d
Why oral semaglutide needs an absorption enhancer at all — one year on
Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. Reading back through what has been written here…
SCSOOFJREF+11 15 17k 24d
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset
Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Something about Oral versus…
BFAFMNCLAI+27 31 17k 25d
Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? — that is the question, and I have not found it answered plainly anywhere I have looked. Setting out what I think I know about this compound and asking…
JSRASMNAKF+5 9 13k 25d
Journal club: STEP 3 and the intensive behavioural therapy floor
Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Two things I would like separated before anyone answers…
LSDOJFPWCL+6 10 13k 28d
Does dual agonism explain the effect size, or is it dose?
Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. A question about dual agonism that I think has a definite…
CGBIBTYSO+62 68 2.6k 29d
Coming back to: What the published dose-response for semaglutide actually looks like above 2.4 mg
The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it. I would like to know what…
SCHJSATKO+23 27 9.9k 1mo
Run-in periods and the population they select
On the subject in the title: Run-in periods and the population they select Working notes rather than a conclusion. An honest uncertainty about run-in periods rather than a disguised assertion. I do not know…
DOEVABANLG+130 142 7.3k 1mo
Journal club: SELECT, absolute risk, and how it was reported
Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what they…
MSFVJF 2 52k 1mo
Journal club: SELECT, absolute risk, and how it was reported — a second dataset
On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Posting a small dataset on SELECT. It is mine, it is…
VKJBFNAITH 4 1.3k 1mo
Reading a trial's population section before its results
On the subject in the title: Reading a trial's population section before its results Working notes rather than a conclusion. Reading STEP 2 ( Lancet , 2021) for the population rather than the effect, which I…
WZOCDJBVK+91 109 22k 2mo
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported?
Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Something about Tirzepatide…
BNNSKFCBP+109 122 3.6k 2mo
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. The question about…
EHSBBOARB+3 7 1k 2mo
Why retatrutide discussion here is more cautious than elsewhere
Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. A question about retatrutide discussion that I think…
DSCAKNKN+7 12 7.7k 2mo
Subgroup analyses: pre-specified versus discovered — a second dataset
On the subject in the title: Subgroup analyses: pre-specified versus discovered — a second dataset Working notes rather than a conclusion. Posting a small dataset on Subgroup analyses. It is mine, it is…
IDAMCILDC+71 79 906 3mo
Primary endpoint hierarchies and why order matters
Primary endpoint hierarchies and why order matters Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about primary endpoint hierarchies in a thread last spring and…
LCDSFWCLNK 4 308 3mo
Journal club: is percentage weight change the right endpoint?
Journal club: is percentage weight change the right endpoint? I have a specific reason for asking rather than idle curiosity, and the context is below. Bringing a claim rather than a paper, because the claim…
IFLEDSSBE+116 120 23k 3mo
Follow-up: What a statistical analysis plan adds that the paper does not
What a statistical analysis plan adds that the paper does not I have a specific reason for asking rather than idle curiosity, and the context is below. A follow-up question about statistical analysis plan…
SBEMTT 2 7.2k 3mo
Open-label extensions: what survives and what does not
Posting this under the heading it deserves: Open-label extensions: what survives and what does not Everything below is what sits behind that. I have spent a fortnight trying to pin open-label extensions down…
PQZILUCMB 4 22k 3mo
Oral semaglutide bioavailability and its variability between people
Posting this under the heading it deserves: Oral semaglutide bioavailability and its variability between people Everything below is what sits behind that. I would like to know what people here actually do…
SHNKITAKAD+44 48 574 3mo
Coming back to: Semaglutide in people without diabetes: what the evidence base looks like
On the subject in the title: Semaglutide in people without diabetes: what the evidence base looks like Working notes rather than a conclusion. Two things I would like separated before anyone answers on…
LPNMENALAT+41 46 1.2k 4mo
Run-in periods and the population they select — the long version
Run-in periods and the population they select — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about Run-in periods, deliberately narrow,…
ALFREK 2 8.9k 4mo
Why semaglutide solutions can look faintly opalescent and when that matters
The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it. A follow-up question about…
DNGPRSDTMG+73 79 2k 4mo
Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…
KBDBVBNTIG+128 145 3k 4mo
The most common factual error about semaglutide on the internet — what changed since
The most common factual error about semaglutide on the internet — what changed since — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a…
SKBOSBBDAL+42 46 1.7k 5mo
Journal club: PIONEER 6 as a safety trial
Posting this under the heading it deserves: Journal club: PIONEER 6 as a safety trial Everything below is what sits behind that. Reading PIONEER 6 ( N Engl J Med , 2019) for the population rather than the…
SCMONMWSH+14 18 262 5mo